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steroidogenesis, mitochondrial permeability transition pore opening and apoptosis. TSPO
ligands have been investigated as therapeutic agents that promote neuroprotective effects
in experimental models of brain injury and neurodegenerative diseases. The aim of this
study was to identify the neuroprotective effects of 40-chlorodiazepam (40-CD), a ligand of
TSPO, against amyloid-beta (Aβ) in SHSY-5Y neuroblastoma cells and its mechanisms of
action. Aβ decreased the viability of SHSY-5Y neuroblastoma cells, while 40-CD had a
neuroprotective effect at the doses of 1 nM and 10 nM. The neuroprotective effects of 40-CD
against Aβ were associated with the inhibition of Aβ-induced upregulation of Bax and
downregulation of survivin. In summary, our ﬁndings indicate that 40-CD is neuroprotec-
tive against Aβ-induced neurotoxicity by a mechanism that may involve the regulation of
Bax and survivin expression.
& 2015 Elsevier B.V. All rights reserved.8
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.D. Arbo).1. Introduction
Translocator protein (TSPO) is an 18 kDa protein located at
contact sites between the outer and the inner mitochondrial
membranes, which was previously known as peripheral benzo-
diazepine receptor (PBR), due to its property to bind diazepam
(Papadopoulos et al., 2006; Batarseh and Papadopoulos, 2010).
This protein is arranged in ﬁve transmembrane alpha helicesand presents a cholesterol recognition amino acid consensus
(CRAC) domain at its C-terminal region, presenting high-afﬁnity
for cholesterol (Li and Papadopoulos, 1998; Jaremko et al., 2014).
Functionally, TSPO is thought to mediate the translocation of
cholesterol across the aqueous mitochondrial intermembrane
space, and due to this function, this protein was renamed in
2006 as TSPO (Papadopoulos et al., 2006). TSPO forms part of a
multiprotein complex, termed the transduceosome, composed
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the mitochondria such as: (i), the voltage-dependent anion
channel (VDAC); (ii), the 67-kDa long isoform of the adenosine
triphosphatase (ATPase) family, AAA domain-containing protein
3 (ATAD3) and (iii), the steroidogenic acute regulatory protein
(StAR) (Midzak et al., 2011; Rone et al., 2012; Issop et al., 2015).
The transport of cholesterol into the mitochondria is the rate-
limiting step in steroidogenesis. In the mitochondria, the bio-
synthesis of steroids is initiated with the enzymatic cleavage of
the side chain of cholesterol by the cytochrome P450 side chain
cleavage enzyme (CYP11A1), which forms the ﬁrst steroid,
pregnenolone (Miller and Auchus, 2011). Pregnenolone, then,
leaves the mitochondria towards the endoplasmic reticulum,
where it undergoes further enzymatic transformations that will
form the ﬁnal steroid products, including progesterone, testos-
terone and estradiol (Lacapère and Papadopoulos, 2003).
In addition to its relationship with the regulation of choles-
terol transport and steroidogenesis, TSPO is thought to mediate
other mitochondrial functions, such as mitochondrial respiration
and cell proliferation and differentiation (Hirsch et al., 1989; Corsi
et al., 2008). Moreover, TSPO has been associated with the control
of themitochondrial permeability transition pore (MPTP) opening,
therefore regulating cytochrome C release, caspase activation and
apoptosis (Zamzami and Kroemer, 2001; Azarashvili et al., 2007;
Sileikyte et al., 2011).
TSPO is widely distributed throughout the body, being found in
most tissues, including the adrenal, pineal and salivary glands,
the olfactory epithelium, ependyma, gonads, heart, kidney, liver,
lung, bone, marrow, brain, spinal cord and peripheral nerves
(Batarseh and Papadopoulos, 2010; Hernstadt et al., 2009). In the
nervous system, the expression of TSPO in physiological condi-
tions is low, however, this protein is upregulated at sites of injury
and inﬂammation, as well as in several neuropathological condi-
tions including stroke and neurodegenerative disorders such as
Alzheimer's disease (AD), Parkinson's disease, Huntington's dis-
ease, multiple sclerosis and amyotrophic lateral sclerosis (Gerhard
et al., 2006; Pavese et al., 2006; Edison et al., 2008; Yasuno et al.,
2008; Rissanen et al., 2014; Zürcher et al., 2015). Some studies have
shown that TSPO ligandsmay be neuroprotective in experimental
models of different neurodegenerative diseases, as well as in
experimental models of brain injuries and psychiatric disorders
(see Arbo et al. (2015) for review). In addition, Girard et al. (2008)
have shown that the TSPO ligand etifoxine is able to improve
nerve regeneration and functional recovery after nerve transec-
tion in rats. Furthermore, Giatti et al. (2009) demonstrated that the
TSPO ligand 40-chlorodiazepam (40-CD, also known as Ro5-4864) is
able to increase the levels of pregnenolone, progesterone and
dihydrotestosterone in the sciatic nerves of diabetic rats and to
decrease the severity of diabetic peripheral neuropathy. In relation
to AD, it was observed that 40-CD exerts neuroprotective actions in
a mouse model of AD, reducing hippocampal amyloid-beta (Aβ)-
40 accumulation and gliosis, and improving the functional out-
comes of 3xTgAD mice (Barron et al., 2013).
AD pathological hallmarks include the presence of extracel-
lular senile plaques mainly composed of Aβ peptide and intra-
cellular neuroﬁbrillary tangles formed by hyper-phosphorilated
aggregates of tau, which is a microtubule-associated protein
(Cavallucci et al., 2012). Aβ accumulation causes neuronal damage
in AD through the activation of pro-apoptotic pathways (Nikolaev
et al., 2009; Vohra et al., 2010; Zhou et al., 2011) and contributes tothe formation of intracellular neuroﬁbrillary tangles, which
further accelerates neuronal loss and causes the symptoms of
dementia (Takata and Kitamura, 2012). It is known that Aβ
downregulates the expression of Bcl-2, an anti-apoptotic protein,
and upregulates the expression of Bax, a pro-apoptotic protein,
regulating neuronal survival through the modulation of the
balance between pro-apoptotic and anti-apoptotic proteins
(Paradis et al., 1996; Selznick et al., 2000; Clementi et al., 2006).
Therefore, the aim of this study was to identify the neuroprotec-
tive effects of 40-CD against amyloid-beta (Aβ) in SHSY-5Y
neuroblastoma cells and its mechanisms of action.2. Results
2.1. 40-CD is neuroprotective against Aβ induced
neurotoxicity
To assess its neuroprotective effects, four different doses of
40-CD were tested against Aβ-induced neurotoxicity. It was
observed that 40-CD was neuroprotective against Aβ when
administered at 1 nM or 10 nM (F(6,30)¼8.093, Po0.0001)
(Fig. 1). However, when cells were treated with higher doses
of 40-CD (100 nM or 1 μM), its neuroprotective effect disap-
peared. Based on these ﬁndings, we selected the dose of
10 nM to be used in the subsequent experiments.
2.2. The neuroprotective effect of 40-CD against Aβ is
related with the modulation of the protein expression of Bax
and survivin
After the identiﬁcation of the neuroprotective effect elicited by 40-
CD administration against Aβ-induced neurotoxicity, we studied
the expression of some proteins implicated in the regulation of
cell survival and apoptosis, namely Bax, survivin, Bcl-xl and
procaspase-3, which could mediate the neuroprotective effects
of 40-CD. We observed that Aβ increased the protein expression of
Bax (F(3,20)¼5.916, P¼0.0046) (Fig. 2) and decreased the protein
expression of survivin (F(3,18)¼3.454, P¼0.0385) (Fig. 3), while the
concomitant administration of 40-CD inhibited these effects. No
differences were found in the expression of Bcl-xl (Fig. 4) and
procaspase-3 (Fig. 5) between the experimental groups.3. Discussion
In the last decade, several studies have assessed the neuropro-
tective actions of TSPO ligands in different experimental models.
These compounds, which are currently used for brain imaging of
neuroinﬂammation due to the upregulation of TSPO in reactive
microglia and astrocytes, have been shown to be neuroprotective
in different experimental models of neurodegenerative diseases,
brain injuries and psychiatric disorders (as reviewed by Arbo
et al. (2015). In this study, we observed that the TSPO ligand 40-CD
was neuroprotective against Aβ treatment in female human
neuroblastoma cells. These data corroborate previous data by
Barron et al. (2013), which found that 40-CD was neuroprotective
in a mouse model of AD, reducing hippocampal Aβ-40 accumula-
tion and gliosis, and improving the functional outcomes of
3xTgAD mice.
Fig. 1 – Effect of different doses of 40-CD in the viability of SHSY-
5Y cells exposed to Aβ. Cells were pre-treated with vehicle or
different doses of 40-CD for 1 h, and then treated with vehicle or
40-CD and exposed to Aβ (1–40) (12 μM) for 24 h. At least four
independent experiments were performed. Data represent the
mean7SEM and are expressed as percentage of control values.
#Different fromDMSO; *Different fromAβ (ANOVA/SNK, Po0.05).
Fig. 2 – Effect of 40-CD in the protein expression of Bax in SHSY-
5Y cells exposed to Aβ. Cells were pre-treated with vehicle or 40-
CD (10 nM) for 1 h, and then treated with vehicle or 40-CD
(10 nM) and exposed to Aβ (1–40) (12 μM) for 24 h. Data represent
the mean7SEM. *Different from other groups (n¼5–6/group;
ANOVA/SNK, P¼0.0046).
Fig. 3 – Effect of 40-CD in the protein expression of survivin in
SHSY-5Y cells exposed to Aβ. Cells were pre-treated with
vehicle or 40-CD (10 nM) for 1 h, and then treated with
vehicle or 40-CD (10 nM) and exposed to Aβ (1–40) (12 μM) for
24 h. Data represent the mean7SEM. *Different from other
groups (n¼6/group; ANOVA/SNK, P¼0.0385).
Fig. 4 – Effect of 40-CD in the protein expression of Bcl-xl in
SHSY-5Y cells exposed to Aβ. Cells were pre-treated with
vehicle or 40-CD (10 nM) for 1 h, and then treated with
vehicle or 40-CD (10 nM) and exposed to Aβ (1–40) (12 μM) for
24 h. Data represent the mean7SEM (n¼5–6/group).
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neuronal survival through the modulation of the balance
between pro-apoptotic and anti-apoptotic proteins (Paradis
et al., 1996). We observed here that Aβ neurotoxicity wasassociated with a decreased expression of survivin, which
was reversed by the co-administration of 40-CD. Survivin is a
downstream protein of the β-catenin pathway and a member
of the inhibitor of apoptosis protein family, which exerts
Fig. 5 – Effect of 40-CD in the protein expression of
procaspase-3 in SHSY-5Y cells exposed to Aβ. Cells were
pre-treated with vehicle or 40-CD (10 nM) for 1 h, and then
treated with vehicle or 40-CD (10 nM) and exposed to Aβ (1–
40) (12 μM) for 24 h. Data represent the mean7SEM (n¼6/
group).
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activated caspases, including caspase-3 and -7 (Tamm et al.,
1998; Shin et al., 2001). Although we did not observe changes
in the levels of procaspase-3, survivin could be acting mod-
ulating its cleavage into the active caspase-3, whose levels
were not detected in the Western-blots. Indeed, data suggest
that although survivin tightly binds to active caspases such
as caspase-3 and -7, it may not bind to its inactive proforms,
acting mainly by inhibiting the activated caspases and
regulating caspase activation by preventing the cleavage of
its proforms (Tamm et al., 1998). Therefore, this could explain
the fact that the changes in the levels of survivin were not
correlated with signiﬁcant differences between the levels of
procaspase-3. In addition, it should be mentioned that the
role of caspase-3 in the Aβ-induced neuronal death is still
controversial, as studies have suggested that Aβ neurotoxicity
may be also caspase-independent (Selznick et al., 2000;
Dumanchin-Njock et al., 2001; Yu et al., 2010; Yu et al., 2011).
In addition to the modulation of survivin protein expres-
sion, the neuroprotective effects of 40-CD were also associated
with a decreased protein expression of Bax. As previously
mentioned, several studies have shown that Aβ-induced
neuronal damage is associated with the modulation of the
balance between pro-apoptotic and anti-apoptotic proteins,
including the upregulation of Bax and the downregulation of
anti-apoptotic proteins from the Bcl-2 family (Paradis et al.,
1996; Selznick et al., 2000; Clementi et al., 2006). Bax is a pro-
apoptotic protein from the Bcl-2 protein family that is found
mainly in the cytosol as soluble monomers, and to a lesser
extent, loosely associated to mitochondria (Dejean et al.,2006). Bax activity is under the control of prosurvival mem-
bers of the Bcl-2 family, including Bcl-2 and Bcl-xl, which
heterodimerize with Bax and other pro-apoptotic proteins,
inhibiting their activation (Chipuk et al., 2010). After apoptotic
stimulation, Bax undergoes conformational changes and is
translocated from the cytosol to the mitochondria, where it
regulates the formation of pores and leads to the mitochon-
drial outer membrane permeabilization (MOMP), resulting in
the release of cytochrome c and other pro-apoptotic factors
from the mitochondria, which lead to caspase activation and
apoptosis (Gillies et al., 2015). Therefore, the neuroprotective
actions of 40-CD against Aβ could be related with a down-
regulation of Bax expression, which could be associated with
decreased cytochrome c release and increased cell viability.
Although the changes in the Bax expression were not directly
related to signiﬁcant changes in the expression of Bcl-xl,
other proteins of the Bcl-2 family such as Bcl-2 could be
involved in the regulation of Bax expression after 40-CD
treatment.
As previously mentioned, functionally, TSPO is thought to
regulate cholesterol transport and steroidogenesis (Midzak
et al., 2011; Rone et al., 2012; Arbo et al., 2015). Therefore, one
of the hypothesis regarding the neuroprotective effects of
TSPO ligands against Aβ is that the activation of TSPO could
be related with the stimulation of the biosynthesis of neuro-
steroids, which could mediate the neuroprotective effects of
TSPO ligands. Regarding this aspect, it is known that estradiol
is able to regulate the expression of proteins from the Bcl-2
family, decrease mitochondrial cytochrome c release and
protect cortical and hippocampal neurons against Aβ
(Nilsen et al., 2006; Yao et al., 2007). These data were
corroborated by another study, which found that estradiol
protects cerebellar granule cells against Aβ through a reduc-
tion in the Aβ-induced upregulation of Bax and downregula-
tion of Bcl-xl, inhibiting mitochondrial cytochrome c release
and apoptosis (Napolitano et al., 2014). Moreover, Qin
et al. (2015) demonstrated that progesterone is neuroprotec-
tive against Aβ-induced neurotoxicity in primary cultured rat
cortical neurons through the inhibition of JNK signaling and
the inhibition of the mitochondrial apoptotic pathway. More
recently, Grimm et al. (2015) showed that different neuro-
steroids, including progesterone, estradiol and testosterone,
are able to rescue the bioenergetics deﬁcits induced by the
overexpression of Aβ in SHSY-5Y cells. In addition, other
study showed that both estradiol and progesterone are able
to regulate the expression of Aβ clearance factors in primary
neuron cultures and female rat brain (Jayaraman et al., 2012),
corroborating a possible role of neurosteroids in the regula-
tion of Aβ actions in the brain. On the other hand, it is also
known that neurosteroidogenesis is affected by Aβ in SH-
SY5Y cells (Schaeffer et al., 2008) and that 3xTg-AD mice
show age-related changes in neuroactive steroid levels
(Caruso et al., 2013), corroborating the relationship between
Aβ and these molecules. Therefore, as 40-CD elicit neuropro-
tection against Aβ through similar mechanisms than neuro-
steroids, including the modulation of the balance between
pro-apoptotic and anti-apoptotic proteins, it is possible that
these effects could be mediated by increased neurosteroido-
genesis, and this hypothesis should be tested by further
studies.
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against Aβ-induced neurotoxicity and that this effect may be
related with the inhibition of Aβ-induced downregulation of
survivin and upregulation of Bax. Further studies may inves-
tigate if the neuroprotective effects of 40-CD against Aβ are
mediated by increased neurosteroidogenesis related to the
stimulation of TSPO activity.4. Experimental procedure
4.1. Chemicals
Dimethyl sulfoxide (DMSO), 40-CD, retinoic acid (RA), ﬂuor-
escein diacetate (FDA) and propidium iodide (PI) were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). Culture
mediums were purchased from Invitrogen (Invitrogen, Crewe,
UK). Aβ1–40 was supplied by Polypeptide (Strasbourg, France).
4.2. Cell cultures
Female human SH-SY5Y neuroblastoma cells (American Type
Culture Collection, Manassas, VA, USA) were grown in Dul-
becco's Modiﬁed Eagle Medium/Nutrient F-12 Ham (DMEM
F12) supplemented with 10% heat-inactivated fetal bovine
serum (FBS) and 1% of antibiotics. Cells were maintained at
371 C in a saturated humidity atmosphere containing 95% air
and 5% CO2. They were passaged twice per week and were
not used after 10 passages.
4.3. Evaluation of the neuroprotective effects of 40-CD
against Aβ induced neurotoxicity
After reaching 80% conﬂuence, cells were seeded into 48-well
plates (for viability assays) or into 6-well plates (for Western
Blot analysis). In order to obtain differentiated cells, they
were cultured with RA (10 μM) for six days as described
elsewhere (Guarneri et al., 2000; Jantas et al., 2014) and the
culture medium was changed every two days during this
period. Five hours before treatments, cells were washed with
phosphate buffered solution (PBS) and incubated with fresh
serum-free medium. Cells were pre-treated for 1 h with
DMSO or 40-CD (1 nM, 10 nM, 100 nM and 1000 nM), and then
exposed to vehicle (PBS) or Aβ1–40 (12 μM, solubilized in PBS at
37 1C for 24 h in order to obtain aggregated Aβ) plus DMSO or
40-CD in the doses previously described for 24 h. The dose of
Aβ used in this study was based in a pilot study (data not
shown).
4.4. Cell viability assays
To assess cell viability we performed the ﬂuorescein diacetate
(FDA)/propidium iodide (PI) assay (Astiz et al., 2014). FDA is a
cell-permeant esterase substrate that stain live cells. Living
cells actively convert the non-ﬂuorescent FDA into the green
compound ﬂuorescein. FDA assay allows the evaluation of
cell-membrane integrity, which is required for intracellular
retention of its ﬂuorescent product. In contrast, PI is a
membrane impermeable compound commonly used for the
identiﬁcation of dead cells. After treatments, cells wereincubated for 50 min at 37 1C with FDA (100 μM) and PI
(15 μM). After that, cells were washed with culture medium
and plates were read in a ﬂuorimeter. The viability ratio is
expressed by the ratio of the FDA/PI absorbance and is given
as percentage of control, and at least four independent
experiments were performed.4.5. Western blotting
After viability assay, cells were homogenized in lysis buffer
(pH 7.4) containing protease inhibitors and detergents
(150 mM NaCl, 20 mM Tris–HCl, 5 mM EDTA, 10% glycerol,
0.5% Nonidet P40 and protease inhibitor cocktail). The homo-
genates were centrifuged at 14000g for 5 min at 4 1C to
discard cell debris, and the supernatant fraction obtained was
used for Western blot assay. After protein isolation, the
samples were boiled for 5 min. The protein levels were
measured by the method of Bradford (1976). After protein
measurement, sodium dodecyl sulfate polyacrilamide gel
electrophoresis (SDS-PAGE) on 12 or 15% (w/v) was carried
out using a mini-protean system (Bio-Rad, Hercules, CA, USA)
with broad range molecular weight standards (Precision Plus
Protein Dual Color Standards, Bio-Rad). Protein (25 mg) was
loaded in each lane with loading buffer containing 65 mM
Tris (pH¼6.8), 50% glycerol, 10% SDS, 0.5 M mercaptoethanol,
0.002% bromophenol blue. Samples were heated at 94 1C for
2 min prior to gel loading. After electrophoresis, proteins
were transferred to 0.2 μm nitrocellulose membranes
(Trans-Blot, Bio-Rad) by a semi-dry system 25 V, 2.5 A, 5 min
(Trans-Blot Turbo Transfer System, Bio-Rad). The membranes
were blocked with 5% (w/v) BSA in TTBS (138 mM NaCl,
25 mM Tris, pH 8.0, and 0.1% (w/v) Tween-20) at room
temperature for 2 h, and then incubated overnight at 4 1C
with the primary antibody diluted in this same blocking
solution. The membranes were processed for immunodetec-
tion using rabbit polyclonal antibodies for survivin (16 kDa)
(1:1000 dilution) (Cell Signaling, Danvers, MA, USA), Bax
(23 kDa) (1:500 dilution) (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), Bcl-xl (30 kDa) (1:50 dilution) (Santa Cruz)
and procaspase-3 (32 kDa) (1:1000 dilution) (BD Biosciences,
San Jose, CA, USA). After washing with TTBS, the membranes
were incubated for 2 h at room temperature with goat anti-
rabbit (Jackson ImmunoResearch, West Grove, PA, USA) or
goat anti-mouse (Bio-Rad) peroxidase-conjugate secondary
antibodies (1:10000 dilution) and washed with TBS (20 mM
Tris–HCl, 140 mM NaCl, pH¼7.4). The blots were revealed for
chemiluminescence followed by apposition of the mem-
branes to autoradiographic ﬁlms (Hyperﬁlm ECL, Amersham).
The densitometric analysis of the autoradiographies was
performed with the image ImageJ software (NIH, Bethesda,
MD, USA). The results from each membrane were normalized
to β-actin (42 kDa) (1:4000 dilution) (Sigma-Aldrich) or glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) (36 kDa)
(1:1000 dilution) (Millipore, Billerica, MA, USA) where indi-
cated. To minimize interassay variations, samples from all
experimental groups were processed in parallel. Protein
expression values were calculated as arbitrary densitom
etric units.
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Statistical analysis was carried out using GraphPad Prism 5.0 soft-
ware (La Jolla, CA, USA). A one-way analysis of variance (one-way
ANOVA) was performed to evaluate cell viability and protein
expression between different groups. When appropriate, ANOVA
was followed by the Student–Newman–Keuls (SNK) post hoc test.
All results were expressed as mean7standard error (SEM). The
level of statistical signiﬁcance was set at Po0.05.Acknowledgments
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